Was The Hype Justified?
Just over 10 years a new approach, Adaptive Trial Design, was going to revolutionise drug development but has it? Here are my...
Phase I oncology – a statistical disaster zone?
The traditional 3+3 design, and its variants such as the rolling-6, have been widely, almost routinely used in phase I oncology trials...
